Imagine a world in which a tiny nanorobot could deliver a specific cannabinoid directly to your endocannabinoid (ECS) receptors. The nanorobot would be thousands of times smaller than the breadth of a human hair and could carry its small cargo inside a single droplet of liquid to deliver it directly to a target cell such as a cancer cell.
Sound far-fetched? It may be closer than you think, because researchers are making great strides in the fascinating field of nanomedicine.
The cannabis plant contains an amazing group of cannabinoids, terpenes, and flavonoids, and scientists are only beginning to unlock the complex pharmacology and potential of these compounds. Combined with nanomedicine, cannabis has even more potential to treat disease and provide overall health benefits for people.
Scientists can manipulate substances on an atomic scale, in the range of 1-100 nanometers, or one thousand times thinner than a sheet of paper. According to the US Nanotechnology Initiative, substances on the nanoscale have very different properties than bulk substances dounique properties like better electrical conductance, higher strength, and different magnetic properties, light reflection, or chemical reactivity. Nanotechnology can be performed on solids, liquids, or gases to unlock these unique phenomena.
For these reason, nanotechnology applications in medicine offer exciting promise and possibilities, especially when applied to cannabis compounds. Many nanotechnology applications are already in usecomputer circuits made from carbon nanotubes allow for far greater computing power, and nanoparticles are already being used in pharmaceuticals to improve absorption.
Researchers work on all kinds of aspects of nanotechnology, such as finding the best substance for nanoparticles, the best shape for a nanoparticle for a specific delivery, and the best transfer mechanisms for specific drugs. Nanoparticles can generate heat, deliver stem cells, be radioactive or metallic, and so much more.
While many applications are still only imagined by scientists, at its full potential, nanotechnology could be the next medical revolution, vastly changing how diseases are detected and treated.
One of the best applications of nanomedicine is in the area of drug delivery, whereby nanoparticles deliver substances directly to specific cells, like diseased cancer cells. Researchers can engineer nanoparticles to be attracted to a diseased cell and limit the ability to bind with and therefore damage healthy cells.
Scientists at MIT and other institutions have successfully used specific nanoparticles to deliver drugs to tumors. Even more interesting is that nanoparticles are developed to work togetherwhile one locates a tumor, another can use the signal from the first to effectively carry the drug to its intended target.
In one interesting application, scientists have created a nanoparticle that looks for hydrogen peroxide present in inflamed tissue, then it releases a drug in that environment to target heart disease.
There is great promise that nanotechnology and cannabinoids can make an impact on diseases like cancer, multiple sclerosis, Parkinsons, diabetes, and a wide range of serious inflammatory diseases.
Nanotechnology can help identify a disease at an early stage, perhaps even when a single cell has gone awry, and then deliver a targeted cannabinoid to correct a cells behavior, thus stopping the disease in its tracks. It may even be possible for a nanorobot to target a specific endocannabinoid receptor to shut down the entire inflammatory process for the betterment of a patient.
Cannabinoid nanodelivery systems have entered the research mainstream, with scientists working on biologically engineered cannabinoids and other nanoparticles to be transported to cells, and by creating nanocarrier transport substances out of metallics or other substances.
Delivery system research also touches on improving bioavailabilitythe rate at which the active substance of a drug enters the bloodstreamas well as improving the physical stability of nanoparticles and optimizing routes of administration, including injection, pills, or sublingual drops.
A nanotechnology-based targeted drug delivery system can be formulated to deliver cannabinoids directly to endocannabinoid receptors, where the magic happens. Cannabinoids can be packed inside a nanoparticle and carried to its intended target without degradation and with a controlled release.
For example, nanoemulsions are already used in the food industry to deliver probiotics or other bioactive ingredients in a very controlled release. These nanoemulsions use a combination of two liquids that dont normally combinesuch as oil and waterto serve as a barrier to chemical degradation for the cannabinoid while on its journey through the body.
Other encapsulation methods can help with potency issues by increasing absorption, they can help decrease side effects, and they can help cover a substances bitter taste.
Specific cannabis strains could even have tailored therapeutic profiles, and cannabinoids could be bioengineered to produce enhanced effects.
Scientists envision a superclass of cannabinoid nanocarriers that have potential to treat a wide array of endocannabinoid insufficiency issues and thus a wide variety of diseases.
In one example, researchers are looking at novel ways to deliver substances across the difficult blood-brain barrier. This barrier is the bodys built-in defense mechanism to protect the brain, so the ability to transport substances across it directly affects a treatments efficacy.
To this end, scientists are engineering lipid nanocapsules decorated with minute cannabinoids like CBD as novel therapies for diseases of the central nervous system.
Nanotechnology has already transformed drug delivery in profound ways, and cannabinoid delivery is part of this exciting future. There are challenges, of course. Cannabinoids quickly degrade in water and are susceptible to other kinds of degradation, and that presents delivery issues.
More recent discoveries, including the decoding of the cannabis genome, discovery of the main CB1R and CB2R receptors within the human endocannabinoid system (ECS), and discovery of other receptors, are also foundational efforts that contribute to cannabinoid nanotechnology.
The latest research shows great progress in the formulation of targeted cannabinoid-nanocarrier delivery systems, and as such may provide key therapies particularly for central nervous system disorders. As scientists continue to make improvements in both bio-efficacy and bioavailability, cannabis nanotechnology represents an exciting and brave new world.
Read this article:
How can nanomedicine be applied to cannabis? - Leafly
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments